RESEARCH STATUSFor research use only. Not for human consumption. Retatrutide is investigational and not FDA-approved.
Y / 002 — RESEARCH BLEND

GLOW

A three-component research blend bringing together distinct peptide pathways. The combination itself has not been validated in human clinical trials.

3COMPONENTS
FORMULATION EVIDENCE BY COMPONENT

SEPARATE THE BLEND.
STUDY EACH PATHWAY.

01Preclinical

GHK-Cu

50 mg / Copper-binding tripeptide

Studied in cell and animal models involving extracellular matrix signaling, collagen-related activity, inflammation, and wound repair. Evidence varies by formulation and route.

02Preclinical

BPC-157

10 mg / Synthetic pentadecapeptide

Published work is overwhelmingly preclinical. A 2025 systematic review found 35 preclinical studies and one small clinical study, with no established clinical safety profile.

03Preclinical

TB-500

10 mg / Thymosin β4-related research peptide

Thymosin β4 research describes roles in cell migration, actin binding, angiogenesis, inflammation, and tissue-repair models. A retail TB-500 blend is not equivalent to an approved human therapy.

THE KEY DISTINCTION

PROMISING DOES NOT
MEAN PROVEN.

Cell and animal findings can explain why a compound interests researchers, but they do not establish a safe dose, clinical effectiveness, or acceptable risk in people. No human-use claim should be inferred from this page.

RESEARCH SNAPSHOT WHAT THE REVIEWS SAY

BPC-157

A systematic review found the musculoskeletal literature was nearly entirely preclinical and reported no clinical safety data.

Open review ↗

THYMOSIN β4

Animal and cell studies describe migration, collagen deposition, angiogenesis, and wound-repair pathways; translation to retail TB-500 products is unestablished.

Open study ↗

GHK-Cu

Recent biomaterials research continues to study inflammation, cell migration, collagen deposition, and tissue repair in preclinical systems.

Open study ↗